Understanding the basic mechanisms of diseases is the fundamental basis to optimize medical treatment. Translational research bridges basic science with applied medicine and thus helps to develop new diagnostic tools and to enhance medical treatments for patients. 

Hamad Medical Corporation’s (HMC) Translational Research Institute (TRI) is proud to have gathered an expert team of basic and physician scientists who perform forefront research in a broad range of medicine including surgical diseases, metabolic disorders, cardio-vascular disorders, immunology, inflammatory diseases including dermatology and rheumatology, as well as neurosciences.

To study important diseases, the TRI features various institutes and state-of-the-art core facilities, such as; proteomics, genomics, metabolomics, molecular physiology, immunohistochemistry/fluorescence, microscopy and flow cytometry. Using a systems and personalized medicine approach, the TRI maximizes our possibility to study diseases and to find better treatments for patients in need.

To optimize therapies for multifactorial, acute or chronic diseases and particular disease phenotypes, it is critical to identify new, evidence-based and personalized treatments. Here, the TRI established an innovative platform to study diseases and its comorbidities with complex molecular interfaces in an interdisciplinary manner. Clinical studies and controlled clinical trials will then lead to a better patient outcome, more effective, safer and more cost-effective treatments for patients.

State-of-the-art lectures by expert scientists and physicians for the public avoiding complicated medical terminologies, emphasizes the obligation of science and physicians to educate our society and spread awareness about scientific developments and to prevent diseases.​